SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
兴奋的以菱
Lv1
80 积分
2022-10-30 加入
最近求助
最近应助
互助留言
LAG-3 as the third checkpoint inhibitor
20天前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2个月前
已完结
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists
2个月前
已完结
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
2个月前
已完结
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy
2个月前
已完结
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
2个月前
已完结
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
2个月前
已完结
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
2个月前
已完结
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
2个月前
已完结
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2个月前
已完结
没有进行任何应助
感谢
20天前
感谢
4个月前
感谢
5个月前
已获得【积分已退回】
6个月前
感谢
6个月前
感谢
10个月前
感谢
1年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论